Biopharma Week in Review - July 15, 2024
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
HilleVax Pre-IPO: Lead Candidate Has Potential to Become First Approved Vaccine for Norovirus
Norovirus vaccine developer, Hillevax, formed by Takeda Pharmaceutical and PE firm Frazier Healthcare Partners, is seeking to raise up to $100...
No more insights